How Will FDA Cuts Affect Your Industry and What Are We Doing to Prepare? – June 2025

LSQLF Meeting: June 2025

In our inaugural meeting of the Life Sciences Quality Leadership Forum, on June 5, 2025, our discussion centered around how the recent cuts to the FDA will affect your industry and what we can do to prepare.

Background

The US Department of Health and Human Services carried out a large-scale reduction-in-force targeting 3,500 FDA employees, accounting for nearly 20% of the agency’s workforce.

• The layoffs primarily affected staff in program management, human resources, technology, policy, communications, and leadership roles with significant institutional knowledge.
• Employees responsible for drug, medical device, and food FDA reviews and inspections were largely spared, but their ability to meet review goals is hindered due to the loss of critical support staff.
• The reduction may slow innovation and access to life-saving devices and treatments, impacting medical advancement and industry operations.
• FDA reviewers and inspectors face challenges adhering to deadlines set by the Prescription Drug User Fee Act due to the removal of key leadership and staff.
• New FDA Commissioner Marty Makary emphasized efficiency, teamwork, and supporting scientists and inspectors but did not address concerns regarding the layoffs’ impact.
• Former FDA acting policy director Eva Temkin warned of consequences such as missed user fee goals, disrupted industry planning, and risks to patient access to timely treatments.
• Industry groups like the Association for Accessible Medicines and the Pharmaceutical Research and Manufacturers of America expressed doubts about the FDA’s capacity to fulfill its mission following the layoffs.

Current Observations

Most people in the discussion indicated no impact on FDA reviews or validation so far, but there are concerns about potential suppression of development due to reduced personnel.

• There have been few or no measurable delays on scientific reviews so far across the companies represented in the meeting.
• There have been observations of increased workload and churn at the FDA due to leadership changes.
• While some timelines are legislatively mandated, there have been indications that these timelines may slip beyond current expectations and commitments.
• Some loss of institutional knowledge has been observed which will have an effect on review consistency.

Concerns

There were a number of concerns identified by the group related to the impact of the FDA cuts. They mainly focused on the potential for delays in the submission and approval process but also extended to the impact on current life sciences company staff who may need to spend more time supporting these processes. There was an overall concern across the board with the impact of the changes being brought on by the new administration.

• Potential impact on supply chain due to tariffs and other governmental changes.
• Concerns about the new director of CBER (Vinay Prasad) being skeptical about fast-track approval.
• Potential of extended approval times beyond the current timelines.
• The potential impact on drug prices and innovation.
• Concerns about the impact on patient access to new medical products, devices, therapies, vaccines, drugs, and biologics.
• Potential restructuring and centralization of activities at the Department of Health and Human Services.

The reduction in staff has led to a loss of institutional FDA knowledge, which may increase the time needed for inspection preparation and extend the overall inspection timeline due to the associated learning curve.

Mitigation Strategies

Participants discussed potential mitigation strategies, including enhancing regulatory planning, monitoring news and agency changes, and adapting product development timelines. Here are some that were discussed:

• Enhancing regulatory planning and strategy.
• Monitoring news and agency changes.
• Adapting product development and launch timelines.
• Maintaining robust documentation and compliance.

Conclusions

In conclusion, the discussions highlighted the multifaceted challenges posed by regulatory changes, particularly with regard to drug submission and approval.  While the near-term effects are currently hard to measure, there are clear indications that there will be impact.  Companies should be considering mitigation strategies such as regulatory planning, timeline adjustments, and active collaboration even while the broader implications of potential restructuring and centralization within health agencies remain uncertain. Proactive engagement and a unified industry approach will be vital in navigating these anticipated hurdles, ensuring the continued advancement and availability of medical interventions.